Leucine-rich repeat kinase-2 (LRRK2) mutations are a common cause of Parkinson's disease. Here we identify inhibitors of LRRK2 kinase that are protective in in vitro and in vivo models of LRRK2-induced neurodegeneration. These results establish that LRRK2-induced degeneration of neurons in vivo is kinase dependent and that LRRK2 kinase inhibition provides a potential new neuroprotective paradigm for the treatment of Parkinson's disease.
Access optionsAccess options
Subscribe to Journal
Get full journal access for 1 year
only $18.75 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Gasser, T. Expert Rev. Mol. Med. 11, e22 (2009).
Greggio, E. et al. Neurobiol. Dis. 23, 329–341 (2006).
Smith, W.W. et al. Nat. Neurosci. 9, 1231–1233 (2006).
West, A.B. et al. Hum. Mol. Genet. 16, 223–232 (2007).
Whaley, N.R., Uitti, R.J., Dickson, D.W., Farrer, M.J. & Wszolek, Z.K. J. Neural Transm. Suppl. 70, 221–229 (2006).
Mata, I.F., Wedemeyer, W.J., Farrer, M.J., Taylor, J.P. & Gallo, K.A. Trends Neurosci. 29, 286–293 (2006).
Chin, P.C. et al. J. Neurochem. 90, 595–608 (2004).
Imai, Y. et al. EMBO J. 27, 2432–2443 (2008).
Smith, W.W. et al. Proc. Natl. Acad. Sci. USA 102, 18676–18681 (2005).
Leclerc, S. et al. J. Biol. Chem. 276, 251–260 (2001).
Wang, W. et al. Neuropharmacology 52, 1678–1684 (2007).
Anand, V.S. et al. FEBS J. 276, 466–478 (2009).
Covy, J.P. & Giasson, B.I. Biochem. Biophys. Res. Commun. 378, 473–477 (2009).
Nichols, R.J. et al. Biochem. J. 424, 47–60 (2009).
Reichling, L.J. & Riddle, S.M. Biochem. Biophys. Res. Commun. 384, 255–258 (2009).
We thank C. Burris and L. Lotta for packaging helper virus–free amplicons. C. Cook, K. Kehoe, J. Dunmore and C. Eckman provided technical support for some of the in vivo HSV studies. We also thank G. and K. Caldwell and S. Hamamichi for helpful discussions. This work was supported by grants from the US National Institutes of Health, P50NS38377, R01ES014470 (K.A.M.-Z.), R01-AG023593 (W.J.B.), R00-NS058111 (A.B.W.), NS36420 (H.J.F.) and Army Medical Research and Materiel Command, DAMD17-02-1-0695 (H.J.F.), the Mayo Foundation and the Michael J. Fox Foundation.
T.M.D. is a paid consultant to Merck KGAA. The terms of this arrangement are being managed by the Johns Hopkins University in accordance with its conflict of interest policies.
About this article
Differences in Stability, Activity and Mutation Effects Between Human and Mouse Leucine-Rich Repeat Kinase 2
Neurochemical Research (2019)
Molecular Neurobiology (2019)
Biochemical Society Transactions (2019)
Biochemical Journal (2019)
Parkinson’s disease-associated LRRK2-G2019S mutant acts through regulation of SERCA activity to control ER stress in astrocytes
Acta Neuropathologica Communications (2019)